Silexion Therapeutics Corp (SLXN) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Silexion Therapeutics Corp is a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers. Its lead product candidate, SIL204, is a second-generation siRNA therapy targeting mutant KRAS. The company operates as a single segment and is classified as a smaller reporting company and an emerging growth company.
During the quarter, the company received regulatory approvals to initiate its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer in Israel and Germany. The trial was initiated in late July 2026, subsequent to the reporting period.
Key Financial Metrics
| Metric (in thousands, except per share) | Six Months Ended June 30, 2026 | Three Months Ended June 30, 2026 | Dec 31, 2025 (Balance Sheet) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(6,284) | $(3,551) | N/A |
| Loss Per Share (Basic & Diluted) | $(12.41) | $(5.17) | N/A |
| Cash and Cash Equivalents | $2,229 | $2,229 | $5,991 |
| Total Assets | $4,246 | N/A | $7,215 |
| Total Liabilities | $4,202 | N/A | $4,612 |
| Shareholders' Equity | $44 | N/A | $2,603 |
| Net Cash Used in Operating Activities | $(6,571) | $(2,925) | N/A |
| Net Cash Provided by Financing Activities | $2,823 | $2,740 | N/A |
Note: The company has no revenue. All financial figures are in U.S. dollars. Share data reflects a 1-for-10 reverse share split effected on May 28, 2026.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased to $6.4 million for the six months ended June 30, 2026, from $3.9 million in the prior year period. This 63% increase was driven primarily by a $1.8 million rise in subcontractor and consultant costs related to the ramp-up for the Phase 2/3 clinical trial (toxicology, GMP manufacturing, CRO setup).
- Financial Income: The company reported net financial income of $145,000 for the six months ended June 30, 2026, compared to financial expenses of $301,000 in the prior year. This shift was due to the revaluation of financial liabilities, specifically the Related Party Promissory Note.
- Liquidity: Cash and cash equivalents decreased from $5.99 million at year-end 2025 to $2.23 million at June 30, 2026, reflecting a net cash burn of $3.75 million over the six-month period.
- Equity: Shareholders' equity declined to $44,000 from $2.6 million at year-end 2025 due to the accumulated net loss, though this was partially offset by equity issuances.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Current cash resources are estimated to fund operations only through the fourth quarter of 2026. The company requires additional capital to fund clinical trials and operations.
- Financing Activities: The company raised approximately $1.9 million via its At-The-Market (ATM) facility and $1.0 million via an induced warrant exercise transaction in the first half of 2026. Subsequent to the quarter, in August 2026, the company completed a public offering raising approximately $2.5 million in gross proceeds.
- Nasdaq Compliance: As of June 30, 2026, shareholders' equity was below the $2.5 million Nasdaq requirement. However, subsequent financing activities (August 2026 offering and ATM sales) restored equity to approximately $3.2 million, addressing the deficiency.
- Legal Proceedings: On June 22, 2026, the Moringa Sponsor (controlled by a former director) filed a claim in the Tel Aviv District Court disputing the conversion of the Related Party Promissory Note into shares and demanding full cash repayment of the principal plus damages. The company intends to defend vigorously.
- Reverse Share Split: A 1-for-10 reverse share split was effected on May 28, 2026, to support the share price and maintain Nasdaq listing compliance.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.2 million cash balance against the projected burn rate for the Phase 2/3 trial initiation and ongoing operations.
- Legal Dispute: Monitor the status of the lawsuit filed by the Moringa Sponsor regarding the $3.4 million promissory note conversion and potential cash repayment demands.
- Financing Execution: Confirm the successful closing and net proceeds of the August 2026 public offering and subsequent ATM sales to ensure Nasdaq equity compliance is sustained.
- Clinical Trial Progress: Track the enrollment and initial data readouts from the Phase 2/3 SIL204 trial initiated in July 2026.
- Dilution Impact: Assess the dilution effects from the recent public offering, ATM sales, and warrant exercises on existing shareholders.